ALS Community Tells FDA ‘We Have No Time To Waste’; Urges Changes in Trial Design and Review Process

Because of the relentless effects of ALS, a diverse group of ALS voices — patients, families, organizations and the community — came together to speak about their experiences with ALS and to urge the FDA to work with them to overcome some of the obstacles faced in ALS research, clinical trials and standards of care.

Categories: Clinical Trials, Research News, Treatments  |  Tags: a diverse group of ALS voices — patients, ALS, ALS clinical trials, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS survivor Robert Anderson, ALS treatments, amyotrophic lateral sclerosis, Because of the relentless effects of ALS, Bob Stehlin, clinical trials and standards of care., Dr. Jonathan Glass, families, fast-track trials ALS, FDA, FDA ALS, Food and Drug Administration, Lou Gehrig's disease, MDA Senior Vice President of Advocacy Annie Kennedy, MDA/ALS Center of Hope in Philadelphia, MDA/ALS Clinic at Methodist Neurological Institute in Houston, Muscular Dystrophy Association MDA, organizations and the community — came together to speak about their experiences with ALS and to urge the FDA to work with them to overcome some of the obstacles faced in ALS research, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Sara M. Feldman, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stan Appel, Steven M. Derks  |  No comments